Accès ouvert
2021
article
OpenAlex
Chengxi Li, Alex J. Callahan, Mark D. Simon, Kyle A. Totaro et autres
Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. …
us, ch
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Chengxi Li, Alex J. Callahan, Kruttika S. Phadke, Bryan H. Bellaire et autres
High Resolution Image Download MS PowerPoint Slide Antisense peptide nucleic acids (PNAs) have yet to translate to the clinic because of poor cellular uptake, limited solubility, and rapid elimination. Cell-penetrating peptides (CPPs) covalently attached to PNAs may facilitate clinical development by improving …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Lindsey R. Robinson‐McCarthy, Alexander J. Mijalis, Gabriel T. Filsinger, Helena de Puig et autres
To meet the challenges imposed by the COVID-19 pandemic, research laboratories shifted their focus and clinical diagnostic laboratories developed and utilized new assays. Nucleic acid-based testing became widespread and, for the first time, was used as a prophylactic measure. We report 15 …
us, nl, gb
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Chengxi Li, Alex J. Callahan, Mark D. Simon, Kyle A. Totaro et autres
Rapid development of antisense therapies can enable on-demand responses to new viral pathogens and make personalized medicine for genetic diseases practical. Antisense phosphorodiamidate morpholino oligomers (PMOs) are promising candidates to fill such a role, but their challenging synthesis limits their widespread application. …
us, ch
(code pays fourni par la source)
Accès ouvert
2021
preprint
OpenAlex
Chengxi Li, Alexander J. Callahan, Kruttika-Suhas Phadke, Bryan H. Bellaire et autres
Peptide nucleic acids (PNAs) are charge-neutral oligonucleotides with emerging potential for treatment of genetic, acquired, and viral diseases, including COVID-19. Their challenging synthesis, however, limits their use for rapid therapeutic intervention and widespread application. Here, we report a highly efficient technology that …
us
(code pays fourni par la source)
Accès ouvert
2021
preprint
OpenAlex
Chengxi Li, Alexander J. Callahan, Kruttika-Suhas Phadke, Bryan H. Bellaire et autres
Peptide nucleic acids (PNAs) are charge-neutral oligonucleotides with emerging potential for treatment of genetic, acquired, and viral diseases, including COVID-19. Their challenging synthesis, however, limits their use for rapid therapeutic intervention and widespread application. Here, we report a highly efficient technology that …
us
(code pays fourni par la source)
2021
other
OpenAlex
Mark D. Simon, Alexander J. Mijalis, Kyle A. Totaro, Daniel L. Dunkelmann et autres
A fully automated flow-based solid phase peptide synthesizer incorporates each amino acid residue in as fast as 40 seconds. This ultra-rapid synthesis time was due to overcoming four major problems associated with the chemistry, mechanical construction, and control of the peptide synthesizer. …
us, gb, jp
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Lindsey R. Robinson‐McCarthy, Alexander J. Mijalis, Gabriel T. Filsinger, Helena de Puig et autres
us, nl, gb
(code pays fourni par la source)
2020
preprint
OpenAlex
Lindsey R. Robinson‐McCarthy, Alexander J. Mijalis, Gabriel T. Filsinger, Helena de Puig et autres
The SARS-CoV-2 pandemic has brought about the unprecedented expansion of highly sensitive molecular diagnostics as a primary infection control strategy. At the same time, many laboratories have shifted focus to SARS-CoV-2 research and diagnostic development, leading to large-scale production of nucleic acids …
us, nl, gb
(code pays fourni par la source)
Accès ouvert
2020
preprint
OpenAlex
Chengxi Li, Alexander J. Callahan, Mark D. Simon, Kyle A. Totaro et autres
The antisense phosphorodiamidate morpholino oligomer (PMO) drugs Eteplirsen and Golodirsen are improving the lives of some Duchenne muscular dystrophy (DMD) patients, but treating all DMD subtypes would require the development of over 50 novel antisense therapies. To rapidly prototype personalized PMO for …
us, ch
(code pays fourni par la source)
Accès ouvert
2020
preprint
OpenAlex
Chengxi Li, Alexander J. Callahan, Mark D. Simon, Kyle A. Totaro et autres
The antisense phosphorodiamidate morpholino oligomer (PMO) drugs Eteplirsen and Golodirsen are improving the lives of some Duchenne muscular dystrophy (DMD) patients, but treating all DMD subtypes would require the development of over 50 novel antisense therapies. To rapidly prototype personalized PMO for …
us, ch
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
William R. Lindemann, Alexander J. Mijalis, José L. Alonso, Peter P. Borbat et autres
RGD is a prolific example of a tripeptide used in biomaterials for cell adhesion, but the potency of free or surface-bound RGD tripeptide is orders-of-magnitude less than the RGD domain within natural proteins. We designed a set of peptides with varying lengths, …
us
(code pays fourni par la source)